Bone metastases from bladder perivascular epithelioid cell tumor – an unusual localization of a rare tumor: a case report

Journal of Medical Case Reports

Antonio Carbone²  Silverio Tomao³  Vincenzo Petrozza⁴  Natale Porta⁴  Claudio Di Cristofano⁴  Luigi Rossi³  Luigi Silvestri¹  Salvatore Evangelista³  Antonio Luigi Pastore⁵  Giovanni Palleschi² 

[1] Department of Biotechnologies and Medico-Surgical Sciences, Urology Unit, ICOT, Sapienza University of Rome, Latina, Italy;Uroresearch® Association, Latina, Italy;Department of Biotechnologies and Medico-Surgical Sciences, Oncology Unit, ICOT, Sapienza University of Rome, Latina, Italy;Department of Biotechnologies and Medico-Surgical Sciences, Histopathology Unit, ICOT, Sapienza University of Rome, Latina, Italy;Department of Medical and Surgical Sciences and Biotechnologies, Unit of Urology, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, LT, Italy

关键词: Perivascular epithelioid cell tumors;    Metastasis;    Chemotherapy;    Bladder;   

Others  :  815226
DOI  :  10.1186/1752-1947-8-227

 received in 2014-02-13, accepted in 2014-05-13,  发布年份 2014

【 摘 要 】

Introduction

Perivascular epithelioid cell tumors are mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. This type of tumor is rare but bladder localization is even rarer.

Case presentation

A case of bone metastatic bladder perivascular epithelioid cell tumor in a 65-year-old Caucasian man treated with surgery and chemotherapy is described and compared with other reports in the literature.

Conclusions

The rarity of perivascular epithelioid cell tumors hinders the development of a standard therapeutic approach, and thus requires case report descriptions. There is a need for cooperative studies to enlarge the case series and establish the best treatment strategy for this rare disease.

【 授权许可】

   
2014 Palleschi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

Figure 2.

【 参考文献 】

• [1]Folpe AL: Neoplasms with perivascular epithelioid cell differentiation (PEComas). In World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Soft Tissue and Bone. Edited by Fletcher CDM, Unni KK, Mertens F. Lyon: IARC Press; 2002:221-222.
• [2]Folpe AL, Kwiatkowski DJ: Perivascular epithelioid cell neoplasms: pathology and pathogenesis. Hum Pathol 2010, 41(1):1-15. doi: 10.1016
• [3]Yin L, Bu H, Chen M, Yu J, Zhuang H, Chen J, Zhang H: Perivascular epithelioid cell neoplasm of the urinary bladder in an adolescent: a case report and review of the literature. Diagn Pathol 2012, 7:183. doi:10.1186/1746-1596-7-183 BioMed Central Full Text
• [4]Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, Lerner HJ, Carbone PP: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987, 5(6):840-850.
• [5]Lopez M, Vici P, Di Lauro L, Carpano S: Increasing single epirubicin doses in advanced soft tissue sarcomas. J Clin Oncol 2002, 20(5):1329-1334.
• [6]Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007, 25(21):3144-3150.
• [7]Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001, 19(15):3483-3489.
• [8]Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, Inbar M: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000, 45(2):177-181.
• [9]Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E: Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002, 94(12):3225-3229.
• [10]Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, Keizer HJ, Hermans C, Van Glabbeke M, Verweij J, Hogendoorn PC, Nielsen OS: Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002, 38(4):556-559.
• [11]Pea M, Martignoni G, Zamboni G, Bonetti F: Perivascular epithelioid cell. Am J Surg Pathol 1996, 20(9):1149-1153.
• [12]Sendo H, Harada H, Hasegawa H, Yasuda T, Ohara T, Oshikiri T, Tanaka K, Fujino Y, Tominaga M: A case of gallbladder metastasis from a malignant perivascular epithelioid cell tumor of the bladder. Nihon Shokakibyo Gakkai Zasshi 2013, 110(5):861-868.
• [13]Folpe AL, Mentzel T, Lehr H, Fisher C, Balzer BL, Weiss SW: Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin. Am J Surg Pathol 2005, 29(12):1558-1575.
• [14]Parfitt JR, Bella AJ, Wehrli BM, Izawa JI: Primary PEComa of the bladder treated with primary excision and adjuvant interferon-alpha immunotherapy: a case report. BMC Urol 2006, 6:20. BioMed Central Full Text
• [15]Gennatas C, Michalaki V, Kairi PV, Kondi-Paphiti A, Voros D: Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. World J Surg Oncol 2012, 10:181. BioMed Central Full Text
• [16]Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F: PEComas: the past, the present and the future. Vircow Virchows Arch 2008, 452(2):119-132.